Vaso Active Bends Truth About Clinical Trial

One claim that reportedly is getting looked at is a repeated comment by Masiz that the company's stock is drawing the interest of institutional investors.

Masiz, in a Feb. 19 press release, said a major rationale for the company's 3-for-1 stock split was the "significant demand for our common stock at the institutional level." Masiz made a similar comment about growing institutional interest in shares of Vaso Active after speaking at an investment conference in Italy in November, one month before the company's IPO.

The earliest investors will be able to see for themselves which institutions are investing in Vaso Active won't be until some time in April. That's the period when big investors must declare their quarterly stock holdings.

But Vaso Active is not the kind of stock to which big institutions normally flock.

For starters, the company is small, has no profits and has sales under $100,000 a year. Termin8 isn't even on store shelves right now and may not be until this summer. It can only be purchased online at the company's Web site for $19.99.

The company also has no Wall Street analysts following it and few shares available to the public. Even after the stock splits, Vaso Active has just 10 million shares outstanding, of which more than half are owned by corporate insiders.

>To order reprints of this article, click here: Reprints